Know Labs (KNW) Company Overview

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), is proud to announce the formation of its new business unit, Know Labs Technology Licensing, (KTL). Modeled after the successful Qualcomm Technology Licensing (QTL) framework, KTL will be dedicated to licensing Know Labs' robust intellectual property (IP) portfolio to corporate partners, academic institutions and research organ.

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended September 30, 2024, which was filed on November 14, 2024 with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company.

SEATTLE--(BUSINESS WIRE)--Know Labs Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards. A Plan for Compliance has been undertaken.

Know Labs, Inc. (NYSE:KNW ) Q3 2024 Results Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Ron Erickson - Chairman and Chief Executive Officer Peter Conley - Chief Financial Officer and Senior Vice President, IP Conference Call Participants Operator Greetings. Welcome to Know Labs's Third Quarter 2024 Earnings Conference Call.

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostics technology, today announced the successful closing of its previously announced underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26, and the partial exercise of the underwriters' opt.